Research.Patient.info

Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML) relapsed or refractory research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
This study is testing a new medicine, NMS-03592088, for people with certain types of blood cancers, Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML), that have come back or haven't responded to other treatments. It's looking at how safe the medicine is and if it helps people get better.
France · Spain · Italy